Pharmaceutical company AbbVie (NYSE: ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.

Is now the time to buy AbbVie? Find out by accessing our full research report, it’s free.

Company Overview

Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE: ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, AbbVie grew its sales at a tepid 3.7% compounded annual growth rate. This wasn’t a great result compared to the rest of the healthcare sector, but there are still things to like about AbbVie.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. AbbVie’s annualized revenue growth of 8.2% over the last two years is above its five-year trend, suggesting some bright spots.

This quarter, AbbVie reported year-on-year revenue growth of 10.2%, and its $16.99 billion of revenue exceeded Wall Street’s estimates by 1.2%.

Looking ahead, sell-side analysts expect revenue to grow 8.5% over the next 12 months, similar to its two-year rate. This projection is particularly healthy for a company of its scale and suggests the market sees success for its products and services.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Adjusted Operating Margin

AbbVie has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 44.3%.

Analyzing the trend in its profitability, AbbVie’s adjusted operating margin decreased by 13 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 6.9 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.

This quarter, AbbVie generated an adjusted operating margin profit margin of 37.9%, down 6.4 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Sadly for AbbVie, its EPS declined by 1.6% annually over the last five years while its revenue grew by 3.7%. This tells us the company became less profitable on a per-share basis as it expanded.

Diving into the nuances of AbbVie’s earnings can give us a better understanding of its performance. As we mentioned earlier, AbbVie’s adjusted operating margin declined by 13 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q2, AbbVie reported adjusted EPS of $3.65, up from $2.97 in the same quarter last year. This print beat analysts’ estimates by 1.2%. Over the next 12 months, Wall Street expects AbbVie’s full-year EPS to grow 40.9% from $10.87 to $15.31.

Key Takeaways from AbbVie’s Q2 Results

It was good to see AbbVie narrowly top analysts’ revenue expectations this quarter. On the other hand, its full-year EPS guidance slightly missed. Overall, this was a weaker quarter. The stock traded down 3.4% to $248.70 immediately following the results.

Is AbbVie an attractive investment opportunity right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).